Which has higher valuation & earnings, SVRA or ACIU?

AC Immune has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.58 N/A AC Immune $4.31M 62.10 -$85.03M -$0.54 N/A

Is SVRA or ACIU more profitable?

Savara has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Savara's return on equity of -90.28% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% AC Immune -245.32% -100.17% -28.36%

Do analysts prefer CVAC or ACIU?

AC Immune has a consensus price target of $7.50, suggesting a potential upside of 185.17%. Given AC Immune's stronger consensus rating and higher probable upside, analysts plainly believe AC Immune is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AC Immune 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable valuation and earnings, CVAC or ACIU?

CureVac has higher revenue and earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CureVac $70.74M 14.78 $175.50M $0.72 6.47 AC Immune $4.31M 62.10 -$85.03M -$0.54 N/A

Is CVAC or ACIU more profitable?

CureVac has a net margin of 199.92% compared to AC Immune's net margin of -245.32%. CureVac's return on equity of -23.03% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets CureVac 199.92% -23.03% -19.09% AC Immune -245.32% -100.17% -28.36%

Is ACIU or KURA more profitable?

AC Immune has a net margin of -245.32% compared to Kura Oncology's net margin of -384.30%. AC Immune's return on equity of -100.17% beat Kura Oncology's return on equity. Company Net Margins Return on Equity Return on Assets AC Immune -245.32% -100.17% -28.36% Kura Oncology -384.30% -207.18% -45.17%

AC Immune (ACIU) Competitors

$2.63 -0.05 (-1.87%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.64 +0.00 (+0.19%)

As of 09/18/2026 07:30 PM Eastern

Compare

ACIU vs. SVRA, CVAC, MLTX, JANX, and KURA

Should you buy AC Immune stock or one of its competitors? AC Immune's main competitors and comparable companies include Savara (SVRA), CureVac (CVAC), MoonLake Immunotherapeutics (MLTX), Janux Therapeutics (JANX), and Kura Oncology (KURA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AC Immune compare to Savara?

Savara (NASDAQ:SVRA) and AC Immune (NASDAQ:ACIU) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Savara has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, AC Immune has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

Savara has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Savara's return on equity of -90.28% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
AC Immune	-245.32%	-100.17%	-28.36%

In the previous week, Savara had 1 more articles in the media than AC Immune. MarketBeat recorded 1 mentions for Savara and 0 mentions for AC Immune. Savara's average media sentiment score of 1.02 beat AC Immune's score of 0.00 indicating that Savara is being referred to more favorably in the media.

Company	Overall Sentiment
Savara	Positive
AC Immune	Neutral

87.9% of Savara shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Comparatively, 4.6% of AC Immune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

AC Immune has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
AC Immune	$4.31M	62.10	-$85.03M	-$0.54	N/A

Savara currently has a consensus target price of $10.00, suggesting a potential upside of 86.22%. AC Immune has a consensus target price of $7.50, suggesting a potential upside of 185.17%. Given AC Immune's higher possible upside, analysts clearly believe AC Immune is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
AC Immune	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Savara beats AC Immune on 9 of the 16 factors compared between the two stocks.

How does AC Immune compare to CureVac?

CureVac (NASDAQ:CVAC) and AC Immune (NASDAQ:ACIU) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, AC Immune has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market.

CureVac has a net margin of 199.92% compared to AC Immune's net margin of -245.32%. CureVac's return on equity of -23.03% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
AC Immune	-245.32%	-100.17%	-28.36%

In the previous week, CureVac's average media sentiment score of 0.00 equaled AC Immune'saverage media sentiment score.

Company	Overall Sentiment
CureVac	Neutral
AC Immune	Neutral

AC Immune has a consensus price target of $7.50, suggesting a potential upside of 185.17%. Given AC Immune's stronger consensus rating and higher probable upside, analysts plainly believe AC Immune is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AC Immune	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

CureVac has higher revenue and earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
AC Immune	$4.31M	62.10	-$85.03M	-$0.54	N/A

17.3% of CureVac shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Comparatively, 4.6% of AC Immune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

CureVac beats AC Immune on 8 of the 14 factors compared between the two stocks.

How does AC Immune compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and AC Immune (NASDAQ:ACIU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

MoonLake Immunotherapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, AC Immune has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market.

MoonLake Immunotherapeutics currently has a consensus target price of $24.57, suggesting a potential upside of 98.32%. AC Immune has a consensus target price of $7.50, suggesting a potential upside of 185.17%. Given AC Immune's stronger consensus rating and higher probable upside, analysts plainly believe AC Immune is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.44
AC Immune	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

MoonLake Immunotherapeutics has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. MoonLake Immunotherapeutics' return on equity of -82.53% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%
AC Immune	-245.32%	-100.17%	-28.36%

In the previous week, MoonLake Immunotherapeutics had 3 more articles in the media than AC Immune. MarketBeat recorded 3 mentions for MoonLake Immunotherapeutics and 0 mentions for AC Immune. MoonLake Immunotherapeutics' average media sentiment score of 0.27 beat AC Immune's score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
MoonLake Immunotherapeutics	Neutral
AC Immune	Neutral

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are held by insiders. Comparatively, 4.6% of AC Immune shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

AC Immune has higher revenue and earnings than MoonLake Immunotherapeutics. AC Immune is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
AC Immune	$4.31M	62.10	-$85.03M	-$0.54	N/A

Summary

MoonLake Immunotherapeutics beats AC Immune on 8 of the 15 factors compared between the two stocks.

How does AC Immune compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and AC Immune (NASDAQ:ACIU) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

In the previous week, Janux Therapeutics had 8 more articles in the media than AC Immune. MarketBeat recorded 8 mentions for Janux Therapeutics and 0 mentions for AC Immune. Janux Therapeutics' average media sentiment score of 0.11 beat AC Immune's score of 0.00 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Janux Therapeutics	Neutral
AC Immune	Neutral

Janux Therapeutics has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Janux Therapeutics' return on equity of -11.89% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
AC Immune	-245.32%	-100.17%	-28.36%

AC Immune has lower revenue, but higher earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	101.43	-$113.62M	-$1.64	N/A
AC Immune	$4.31M	62.10	-$85.03M	-$0.54	N/A

Janux Therapeutics has a beta of 2.53, meaning that its stock price is 153% more volatile than the broader market. Comparatively, AC Immune has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

Janux Therapeutics presently has a consensus target price of $36.46, suggesting a potential upside of 119.78%. AC Immune has a consensus target price of $7.50, suggesting a potential upside of 185.17%. Given AC Immune's higher possible upside, analysts clearly believe AC Immune is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
AC Immune	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Comparatively, 4.6% of AC Immune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Janux Therapeutics beats AC Immune on 13 of the 17 factors compared between the two stocks.

How does AC Immune compare to Kura Oncology?

AC Immune (NASDAQ:ACIU) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

AC Immune currently has a consensus price target of $7.50, suggesting a potential upside of 185.17%. Kura Oncology has a consensus price target of $25.40, suggesting a potential upside of 116.54%. Given AC Immune's higher probable upside, equities analysts plainly believe AC Immune is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

AC Immune has higher earnings, but lower revenue than Kura Oncology. AC Immune is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	62.10	-$85.03M	-$0.54	N/A
Kura Oncology	$67.48M	15.46	-$278.67M	-$3.37	N/A

In the previous week, Kura Oncology had 3 more articles in the media than AC Immune. MarketBeat recorded 3 mentions for Kura Oncology and 0 mentions for AC Immune. Kura Oncology's average media sentiment score of 0.34 beat AC Immune's score of 0.00 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
AC Immune	Neutral
Kura Oncology	Neutral

AC Immune has a net margin of -245.32% compared to Kura Oncology's net margin of -384.30%. AC Immune's return on equity of -100.17% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-245.32%	-100.17%	-28.36%
Kura Oncology	-384.30%	-207.18%	-45.17%

AC Immune has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market.

51.4% of AC Immune shares are held by institutional investors. 4.6% of AC Immune shares are held by insiders. Comparatively, 7.6% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

AC Immune beats Kura Oncology on 9 of the 16 factors compared between the two stocks.

Get AC Immune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACIU vs. The Competition

Export

Metric	AC Immune	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$272.75M	$3.92B	$7.24B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-4.87	14.30	275.79	25.40
Price / Sales	62.10	1,415.50	695.58	114.44
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	4.87	15.45	10.46	6.33
Net Income	-$85.03M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-4.71%	-1.21%	0.59%	1.12%
1 Month Performance	1.94%	-4.42%	-2.01%	-2.67%
1 Year Performance	7.35%	37.81%	18.09%	6.01%

AC Immune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACIU AC Immune	2.2479 of 5 stars	$2.63 -1.9%	$7.50 +185.2%	+4.4%	$272.75M	$4.31M	N/A	106	Positive News
SVRA Savara	2.0644 of 5 stars	$5.25 -1.8%	$10.00 +90.7%	+49.2%	$1.08B	N/A	N/A	70	Positive News
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
MLTX MoonLake Immunotherapeutics	2.0868 of 5 stars	$12.15 -4.2%	$24.57 +102.3%	-77.1%	$1.03B	N/A	N/A	130	News Coverage Analyst Forecast
JANX Janux Therapeutics	3.0504 of 5 stars	$16.69 -3.6%	$36.46 +118.5%	-32.0%	$1.02B	$24M	N/A	113

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACIU) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AC Immune (ACIU) Competitors

ACIU vs. SVRA, CVAC, MLTX, JANX, and KURA

How does AC Immune compare to Savara?

Summary

How does AC Immune compare to CureVac?

Summary

How does AC Immune compare to MoonLake Immunotherapeutics?

Summary

How does AC Immune compare to Janux Therapeutics?

Summary

How does AC Immune compare to Kura Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU vs. The Competition

AC Immune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AC Immune (ACIU) Competitors

ACIU vs. SVRA, CVAC, MLTX, JANX, and KURA

How does AC Immune compare to Savara?

Which has more volatility and risk, SVRA or ACIU?

Is SVRA or ACIU more profitable?

Does the media favor SVRA or ACIU?

Do institutionals & insiders hold more shares of SVRA or ACIU?

Which has higher valuation & earnings, SVRA or ACIU?

Do analysts prefer SVRA or ACIU?

Summary

How does AC Immune compare to CureVac?

Which has more risk & volatility, CVAC or ACIU?

Is CVAC or ACIU more profitable?

Does the media favor CVAC or ACIU?

Do analysts prefer CVAC or ACIU?

Which has preferable valuation and earnings, CVAC or ACIU?

Do insiders & institutionals believe in CVAC or ACIU?

Summary

How does AC Immune compare to MoonLake Immunotherapeutics?

Which has more risk and volatility, MLTX or ACIU?

Do analysts prefer MLTX or ACIU?

Is MLTX or ACIU more profitable?

Does the media favor MLTX or ACIU?

Do insiders and institutionals believe in MLTX or ACIU?

Which has stronger earnings & valuation, MLTX or ACIU?

Summary

How does AC Immune compare to Janux Therapeutics?

Does the media favor JANX or ACIU?

Is JANX or ACIU more profitable?

Which has better valuation & earnings, JANX or ACIU?

Which has more volatility and risk, JANX or ACIU?

Do analysts rate JANX or ACIU?

Do institutionals & insiders believe in JANX or ACIU?

Summary

How does AC Immune compare to Kura Oncology?

Do analysts rate ACIU or KURA?

Which has higher earnings and valuation, ACIU or KURA?

Does the media favor ACIU or KURA?

Is ACIU or KURA more profitable?

Which has more risk & volatility, ACIU or KURA?

Do institutionals and insiders believe in ACIU or KURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU vs. The Competition

AC Immune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools